Two new hepatitis C drugs expected to be approved in the coming weeks should drastically reshape the market and treatment of the disease. Read More

Twenty-five drugmakers have agreed to pay the state of Louisiana more than $88 million to settle Medicaid and Medicare fraud charges lodged against them as part of the state’s continuing crusade to recover funds paid out to drug companies improperly. Read More

In a new “sunshine” bid, Britain’s brand drugmakers will begin disclosing payments made to physicians in connection with the development or sale of medicines, beginning in 2016. Read More

Positive results from the first long-term trial of evolocumab, Amgen’s next-generation heart drug, are heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors. Read More

Kadmon Pharmaceuticals has once again been warned by the FDA for making misleading claims in advertisements, this time for omitting risk information and falsely implying that its hepatitis C drug Ribasphere is a monotherapy. Read More

In the wake of record-breaking numbers of drug shortages, particularly generic injectables, the European Federation of Pharmaceutical Industries and Associations (EFPIA) is advising drugmakers to establish a drug shortage task force. Read More

The Supreme Court Nov. 13 dealt generic giant Teva a major blow as it denied the company’s request to stay a lower court’s ruling that will allow generic versions of the drugmaker’s blockbuster brand drug Copaxone to hit pharmacy shelves in May. Read More

Drugmakers have 13 months to revamp how they track drugs after the Senate voted Nov. 18 to send to President Barack Obama’s desk a measure that would establish a nationwide track-and-trace requirement for prescription drugs. Read More